Cargando…
The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
BACKGROUND: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study wa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231442/ https://www.ncbi.nlm.nih.gov/pubmed/30510398 http://dx.doi.org/10.2147/BTT.S176806 |
_version_ | 1783370222755905536 |
---|---|
author | Heslinga, SC Konings, TC van der Horst-Bruinsma, IE Kamp, O van Halm, VP de Bruin-Bon, HACM Peters, MJ Nurmohamed, MT |
author_facet | Heslinga, SC Konings, TC van der Horst-Bruinsma, IE Kamp, O van Halm, VP de Bruin-Bon, HACM Peters, MJ Nurmohamed, MT |
author_sort | Heslinga, SC |
collection | PubMed |
description | BACKGROUND: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. METHODS: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment. RESULTS: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function. CONCLUSION: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy. |
format | Online Article Text |
id | pubmed-6231442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62314422018-12-03 The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis Heslinga, SC Konings, TC van der Horst-Bruinsma, IE Kamp, O van Halm, VP de Bruin-Bon, HACM Peters, MJ Nurmohamed, MT Biologics Original Research BACKGROUND: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. METHODS: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment. RESULTS: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function. CONCLUSION: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy. Dove Medical Press 2018-11-08 /pmc/articles/PMC6231442/ /pubmed/30510398 http://dx.doi.org/10.2147/BTT.S176806 Text en © 2018 Heslinga et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Heslinga, SC Konings, TC van der Horst-Bruinsma, IE Kamp, O van Halm, VP de Bruin-Bon, HACM Peters, MJ Nurmohamed, MT The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
title | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
title_full | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
title_fullStr | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
title_full_unstemmed | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
title_short | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
title_sort | effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231442/ https://www.ncbi.nlm.nih.gov/pubmed/30510398 http://dx.doi.org/10.2147/BTT.S176806 |
work_keys_str_mv | AT heslingasc theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT koningstc theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT vanderhorstbruinsmaie theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT kampo theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT vanhalmvp theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT debruinbonhacm theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT petersmj theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT nurmohamedmt theeffectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT heslingasc effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT koningstc effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT vanderhorstbruinsmaie effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT kampo effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT vanhalmvp effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT debruinbonhacm effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT petersmj effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis AT nurmohamedmt effectsofgolimumabtreatmentonsystolicanddiastolicleftventricularfunctioninankylosingspondylitis |